Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE wants on the T-wave

This article was originally published in The Gray Sheet

Executive Summary

CMS accepts GE Healthcare's request Aug. 17 to consider national coverage of its Marquette modified moving average (MMA) microvolt T-wave alternans test. MTWA tests are used to risk stratify patients for cardioverter defibrillator implants. Based on lack of evidence, a March 2006 CMS coverage decision excludes the MMA method - cleared for risk stratification in 2003 - and only covers Cambridge Heart's HearTwave II test, which uses a proprietary spectral analysis algorithm (1"The Gray Sheet" March 27, 2006, p. 18). GE says studies published in 2007 show MMA's equivalence to the spectral method. CMS is accepting initial comments on the reconsideration until Sept. 17 and will issue a proposed decision by Feb. 17...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts